New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:02 EDTACTGAcacia reaches settlement with Mallinckrodt over Exalgo
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
06:05 EDTACTGAcacia subsidiary signs settlement agreement with Covidien LP
Acacia Research's (ACTG) Advanced Skeletal Innovations and Bonutti Skeletal Innovations subsidiaries have entered into a settlement agreement with Covidien (COV) LP f/k/a Tyco Healthcare Group, a subsidiary of Medtronic (MDT). The agreement resolves litigation that was pending in the U.S. District Court for the District of Columbia.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use